Janney Capital Initiates Aldeyra Therapeutics With Buy

Janney Capital initiated coverage on

with a Buy rating. The target price for Aldeyra Therapeutics is set to $13. Aldeyra Therapeutics shares have gained 11.53 percent over the past 52 weeks, while the S&P 500 index has surged 10.18 percent in the same period. Aldeyra Therapeutics' shares dropped 3.65 percent to close at $6.87 yesterday.